Matching mechanism of death with mechanism of action: Considerations for drug development for hospitalized heart failure

Journal of the American College of Cardiology

Volumn 64, Issue 15, 2014, Pages 1599-1601

  Greene, Stephen J ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

acute heart failure; mechanism of action; mode of death; outcomes

Indexed keywords

DIGOXIN; PLACEBO; RELAXIN; SERELAXIN; TOLVAPTAN; RECOMBINANT PROTEIN; SERELAXIN PROTEIN, HUMAN;

CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DEFIBRILLATION; DRUG MECHANISM; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME; DEATH, SUDDEN, CARDIAC; FEMALE; MALE;

DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HUMANS; MALE; RECOMBINANT PROTEINS; RELAXIN;

EID: 84908118812     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.06.1199     Document Type: Editorial

References (20)

1. M. Gheorghiade, W.T. Abraham, and N.M. Albert Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2006 2217 2226
2. G.C. Fonarow, and E.D. Peterson Heart failure performance measures and outcomes: real or illusory gains JAMA 302 2009 792 794
3. J.R. Teerlink, G. Cotter, and B.A. Davison Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
4. M.A. Konstam, M. Gheorghiade, and J.C. Burnett Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 2007 1319 1331
5. B.M. Massie, C.M. O'Connor, and M. Metra Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428
6. C.M. O'Connor, R.C. Starling, and A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
7. M. Gheorghiade, M. Bohm, and S.J. Greene Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial JAMA 309 2013 1125 1135
8. G.M. Felker, J.R. Teerlink, and J. Butler Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study J Am Coll Cardiol 64 2014 1591 1598
9. C.M. O'Connor, A.B. Miller, and J.E. Blair Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) program Am Heart J 159 2010 841 849.e1
10. E.B. Schelbert, G.C. Fonarow, and R.O. Bonow Therapeutic targets in heart failure: refocusing on the myocardial interstitium J Am Coll Cardiol 63 2014 2188 2198
11. C.M. O'Connor, W.T. Abraham, and N.M. Albert Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Am Heart J 156 2008 662 673
12. A.E. Epstein, J.P. DiMarco, and K.A. Ellenbogen 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 61 2013 e6 e75
13. N.C. Wang, J.P. Piccini, and M.A. Konstam Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction Am J Ther 17 2010 e78 e87
14. Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 1997 525 533
15. M. Gheorghiade, M. Vaduganathan, and G.C. Fonarow Rehospitalization for heart failure: problems and perspectives J Am Coll Cardiol 61 2013 391 403
16. E.Z. Gorodeski, R.C. Starling, and E.H. Blackstone Are all readmissions bad readmissions? N Engl J Med 363 2010 297 298
17. M. Vaduganathan, S.J. Greene, and A.P. Ambrosy The disconnect between phase II and phase III trials of drugs for heart failure Nat Rev Cardiol 10 2013 85 97
18. S.J. Greene, A.N. Shah, and J. Butler Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries Am Heart J 168 2014 142 149
19. T. Ahmad, M. Fiuzat, and B. Neely Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure J Am Coll Cardiol HF 2 2014 260 268
20. M. Gheorghiade, P.S. Pang, and C.M. O'Connor Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase Am Heart J 161 2011 224 232